Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping review
Pharmacoepidemiology and Drug Safety · 2024-05 · 33 (5)
DOI: 10.1002/pds.5787 ↗Kurz gefasst
Scoping Review in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 09.05.2024. Verfasst von Rosa Gini und 19 weiteren Autor:innen. Beteiligte Einrichtung: ARS Toscana, Florence, Italy. Hauptthemen laut MEDLINE: Pharmacoepidemiology. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: International Society for Pharmacoepidemiology.
Abstract (Originalsprache)
Purpose
Real‐world evidence (RWE) is increasingly used for medical regulatory decisions, yet concerns persist regarding its reproducibility and hence validity. This study addresses reproducibility challenges associated with diversity across real‐world data sources (RWDS) repurposed for secondary use in pharmacoepidemiologic studies. Our aims were to identify, describe and characterize practices, recommendations and tools for collecting and reporting diversity across RWDSs, and explore how leveraging diversity could improve the quality of evidence.
Methods
In a preliminary phase, keywords for a literature search and selection tool were designed using a set of documents considered to be key by the coauthors. Next, a systematic search was conducted up to December 2021. The resulting documents were screened based on titles and abstracts, then based on full texts using the selection tool. Selected documents were reviewed to extract information on topics related to collecting and reporting RWDS diversity. A content analysis of the topics identified explicit and latent themes.
Results
Across the 91 selected documents, 12 topics were identified: 9 dimensions used to describe RWDS (organization accessing the data source, data originator, prompt, inclusion of population, content, data dictionary, time span, healthcare system and culture, and data quality), tools to summarize such dimensions, challenges, and opportunities arising from diversity. Thirty‐six themes were identified within the dimensions. Opportunities arising from data diversity included multiple imputation and standardization.
Conclusions
The dimensions identified across a large number of publications lay the foundation for formal guidance on reporting diversity of data sources to facilitate interpretation and enhance replicability and validity of RWE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ARS Toscana, Florence, Italy.
- Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.
- Department of Epidemiology, RTI Health Solutions, Barcelona, Spain.
- Department of Data Science & Biostatistics, University Medical Center Utrecht, Utrecht, The Netherlands.
- University of Iceland, Reykjavik, Iceland.
- Takeda Development Center Americas, Cambridge, Massachusetts, USA.
ORCID-Profile: Rosa Gini, Romin Pajouheshnia, Helga Gardarsdottir, Dimitri Bennett, Lin Li, Claudia Gulea, Angelika Wientzek-Fleischmann, Marloes T Bazelier, Mehmet Burcu, Caitlin Dodd, Carlos E Durán, Sigal Kaplan, Stephan Lanes, Karine Marinier, Giuseppe Roberto, Kanaka Soman, Xiaofeng Zhou, Robert Platt, Soko Setoguchi, Gillian C Hall
Förderung
- International Society for Pharmacoepidemiology
Zitieren
APA
Gini, R., Pajouheshnia, R., Gardarsdottir, H., Bennett, D., Li, L., Gulea, C., Wientzek-Fleischmann, A., Bazelier, M. T., Burcu, M., Dodd, C., Durán, C. E., Kaplan, S., Lanes, S., Marinier, K., Roberto, G., Soman, K., Zhou, X., Platt, R., Setoguchi, S., & Hall, G. C. (2024). Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping review. Pharmacoepidemiology and Drug Safety, 33(5). https://doi.org/10.1002/pds.5787
Vancouver
Gini R, Pajouheshnia R, Gardarsdottir H, Bennett D, Li L, Gulea C, et al. Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping review. Pharmacoepidemiology and Drug Safety. 2024;33(5). doi:10.1002/pds.5787
BibTeX
@article{Gini2024,
author = {Gini, Rosa and Pajouheshnia, Romin and Gardarsdottir, Helga and Bennett, Dimitri and Li, Lin and Gulea, Claudia and Wientzek-Fleischmann, Angelika and Bazelier, Marloes T and Burcu, Mehmet and Dodd, Caitlin and Durán, Carlos E and Kaplan, Sigal and Lanes, Stephan and Marinier, Karine and Roberto, Giuseppe and Soman, Kanaka and Zhou, Xiaofeng and Platt, Robert and Setoguchi, Soko and Hall, Gillian C},
title = {Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping review},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
volume = {33},
number = {5},
doi = {10.1002/pds.5787}
}
EUVIMED